This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, R. Articles by Frostegård, J. Search for Related Content PubMed PubMed Citation Articles by Wu, R. Articles by Frostegård, J. Related Collections Pathophysiology Risk Factors Other hypertension Other etiology

(Hypertension. 2001;37:154.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Antibodies to Lysophosphatidylcholine Are Decreased in Borderline Hypertension

Ruihua Wu; Carola Lemne; Ulf de Faire; Johan Frostegård

From the Department of Medicine (R.W., J.F.), Unit of Rheumatology, and CMM, Karolinska Hospital; Department of Emergency and Cardiovascular Medicine (C.L., U. de F.), Karolinska Hospital; and Division of Cardiovascular Epidemiology (U. de F.), Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Correspondence to Dr Johan Frostegård, Department of Medicine, Karolinska Hospital, Karolinska Institute, 171 76 Stockholm, Sweden. E-mail johanf{at}rheum.ks.se

Abstract—Atherosclerosis is characterized by infiltration in the lesions of cytokine-producing T cells and macrophages, where oxidized LDL may play an important role. However, little is known about the role of the immune system in the development of hypertension. Lysophosphatidylcholine (LPC) is formed by phospholipase A₂–induced hydrolysis and/or by oxidation of LDL and other phospholipid-containing membranes. The objective of the present study was to investigate the role of antibodies to LPC in borderline hypertension (BHT). Seventy-five men with BHT were compared with 75 age-matched normotensive (NT) men (diastolic blood pressure 85 to 94 and <80 mm Hg, respectively). Antibody levels to LPC of IgM and IgG isotypes and IgG subclasses were determined with ELISAs. BHT men had significantly lower anti-LPC antibody levels of both IgG class (P=0.0002) and IgM class (P=0.0003) than did NT controls. Subclass analysis indicated that IgG₁ (P=0.0005), but not IgG₂, was decreased. Anti-LPC antibodies or immunoglobulin subclasses thereof were negatively associated with atherosclerosis on the basis of intima-media thickness (P=0.02), metabolic factors (P=0.02), smoking (P=0.02), and endothelin (P=0.03). LPC has proinflammatory properties and is toxic at higher concentrations and thus may play a role in atherogenesis. Furthermore, LPC functions as a vasoconstrictor in experimental systems by inhibiting NO-mediated vasorelaxation. An intriguing possibility is that anti-LPC antibodies counteract these effects. Taken together, our data indicate that anti-LPC antibodies may constitute a novel factor in the development of hypertension and atherosclerosis.

Key Words: antibodies • lysophosphatidylcholine • hypertension, borderline • atherosclerosis

This article has been cited by other articles:

				J. H. Han, C. Cao, S. M. Kim, F. L. Piao, and S. H. Kim Attenuation of Lysophosphatidylcholine-Induced Suppression of ANP Release From Hypertrophied Atria Hypertension, February 1, 2004; 43(2): 243 - 248. [Abstract] [Full Text] [PDF]

				J. H. Han, C. Cao, S. Z. Kim, K. W. Cho, and S. H. Kim Decreases in ANP Secretion by Lysophosphatidylcholine Through Protein Kinase C Hypertension, June 1, 2003; 41(6): 1380 - 1385. [Abstract] [Full Text] [PDF]